PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Doses of 240 mg and 480 mg of extract significantly lowered the postprandial positive area under the glucose curve (14% and 22% respectively) and the adjusted peak glucose response (19% and 27% respectively) [PMID:17616771].
Treatment for six months reduced triglyceride levels by 23.66% in non-diabetic and 17.45% in diabetic CKD patients [PMID:25579717].
A tea consisting of IP-PA1 and Salacia significantly decreased plasma glucose levels in diabetic model mice and was studied in humans with high plasma glucose or hyperlipidemia [PMID:22125681].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 17616771 (2007) — Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes. · The American journal of clinical nutrition
- 2.PMID: 25579717 (2015) — Effects of Salacia oblonga on cardiovascular risk factors in chronic kidney disease patients: a prospective study. · Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
- 3.PMID: 36817178 (2023) — Environmentally benign silver bio-nanomaterials as potent antioxidant, antibacterial, and antidiabetic agents: Green synthesis using Salacia oblonga root extract. · Frontiers in chemistry
- 4.PMID: 28082793 (2016) — An Updated Review on the Phytochemistry, Pharmacology, and Clinical Trials of Salacia oblonga. · Pharmacognosy reviews
- 5.PMID: 35612657